• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乳腺人表皮生长因子受体 2 阳性大汗腺癌：基于人群的治疗和结局分析。

HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.

机构信息

Faculty of Health Sciences, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

Kansas University Medical Center, Kansas City, KS, USA.

出版信息

Breast Cancer Res Treat. 2022 Jun;193(2):523-533. doi: 10.1007/s10549-022-06578-4. Epub 2022 Mar 30.

DOI:10.1007/s10549-022-06578-4
PMID:35355162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9090698/
Abstract

PURPOSE

Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort.

METHODS

We used the SEER database to explore the cohorts. Univariate and multivariate analyses were used to assess the survival. Based on ER and PR [steroid receptors/SR/] and HER2 status, we divided the cohorts to match the intrinsic molecular subtypes for comparisons.

RESULTS

We retrieved 259 cases of HER2+/APO. Most HER2+/APO were SR negative (65%). HER2+/APO were more prevalent in the 80+ age group (24.7% vs. 15.7%, p < 0.001). HER2+/SR-/APO had a significantly lower histological grade than the HER2+/SR-/NST (p < 0.001). Breast cancer-related deaths were more prevalent in HER2+/NST (7.8% vs. 3.9%, p = 0.019). This was particularly evident between SR- subgroups (10.4% in HER2+/SR-/NST vs. 4.2% in HER2+/SR-/APO, p = 0.008) and was reaffirmed in breast cancer-specific survival in univariate analysis (p = 0.03). Other than race and SR status, HER2+/APO subgroups did not differ in clinicopathological parameters.

CONCLUSIONS

Our study confirms the rarity of the APO and reveals that SR status in APO does not affect these patients' prognosis. HER2+/APO tumors tend to have a less aggressive phenotype and a more favorable outcome despite a markedly lower ER/PR positivity.

摘要

目的

乳腺大汗腺癌（APO）在 30-50%的病例中表达 HER2。本研究探讨了 HER2+/APO 与匹配的 HER2+/NST 队列的临床病理特征和结局。

方法

我们使用 SEER 数据库来探索队列。使用单变量和多变量分析来评估生存情况。根据 ER 和 PR [类固醇受体/SR] 和 HER2 状态，我们将队列进行分组以匹配内在分子亚型进行比较。

结果

我们检索到 259 例 HER2+/APO。大多数 HER2+/APO 为 SR 阴性（65%）。HER2+/APO 在 80 岁以上年龄组更为常见（24.7%比 15.7%，p<0.001）。HER2+/SR-/APO 的组织学分级明显低于 HER2+/SR-/NST（p<0.001）。HER2+/NST 的乳腺癌相关死亡率更高（7.8%比 3.9%，p=0.019）。这在 SR-亚组之间更为明显（HER2+/SR-/NST 为 10.4%，HER2+/SR-/APO 为 4.2%，p=0.008），在单变量分析中也证实了乳腺癌特异性生存（p=0.03）。除了种族和 SR 状态外，HER2+/APO 亚组在临床病理参数方面没有差异。

结论

我们的研究证实了 APO 的罕见性，并揭示了 APO 中的 SR 状态并不影响这些患者的预后。尽管 ER/PR 阳性率明显较低，但 HER2+/APO 肿瘤往往具有侵袭性较低的表型和更好的结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/c7a9c5d9c7c9/10549_2022_6578_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/91f35a7c33b3/10549_2022_6578_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/9a57088b6ee3/10549_2022_6578_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/cd7b3f3ef567/10549_2022_6578_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/c7a9c5d9c7c9/10549_2022_6578_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/91f35a7c33b3/10549_2022_6578_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/9a57088b6ee3/10549_2022_6578_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/cd7b3f3ef567/10549_2022_6578_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2911/9090698/c7a9c5d9c7c9/10549_2022_6578_Fig4_HTML.jpg

相似文献

1
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.乳腺人表皮生长因子受体 2 阳性大汗腺癌：基于人群的治疗和结局分析。
Breast Cancer Res Treat. 2022 Jun;193(2):523-533. doi: 10.1007/s10549-022-06578-4. Epub 2022 Mar 30.
2
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.基于雌激素受体、孕激素受体和人表皮生长因子受体2的乳腺癌亚型与⁶⁸Ga-RGD PET/CT及¹⁸F-FDG PET/CT功能成像参数的相关性
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1534-43. doi: 10.1007/s00259-014-2744-4. Epub 2014 Mar 21.
3
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.单激素受体阳性乳腺癌的预后较差：与三阴性乳腺癌的结局相似。
BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.
4
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.雌激素受体阳性、孕激素受体阴性和 HER2 阴性乳腺癌的基因组景观和内分泌抵抗亚组。
Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018.
5
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.曲妥珠单抗新辅助治疗 HER2 阳性乳腺癌患者的 HER2 检测方法与病理完全缓解率的相关性。
Breast Cancer Res Treat. 2019 Aug;177(1):61-66. doi: 10.1007/s10549-019-05295-9. Epub 2019 May 29.
6
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.伴有脑转移的乳腺癌：临床病理特征、生存情况及配对生物标志物分析。
Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23.
7
Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.新辅助化疗后局部晚期乳腺癌患者雌激素、孕激素和 HER2 受体状态转换的预后意义：来自沙特阿拉伯一家三级癌症中心的结果。
PLoS One. 2021 Mar 5;16(3):e0247802. doi: 10.1371/journal.pone.0247802. eCollection 2021.
8
Genetic and clinical landscape of ER + /PR- breast cancer in China.中国 ER+/PR- 乳腺癌的遗传和临床特征。
BMC Cancer. 2023 Dec 4;23(1):1189. doi: 10.1186/s12885-023-11643-2.
9
The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.雌激素阴性/孕激素阳性（ER-/PR+）表型的预后和预测价值：单中心 1159 例原发性乳腺癌的经验。
Breast J. 2022 May 17;2022:9238804. doi: 10.1155/2022/9238804. eCollection 2022.
10
MYC amplification in subtypes of breast cancers in African American women.非洲裔美国女性乳腺癌亚型中的 MYC 扩增。
BMC Cancer. 2018 Mar 9;18(1):274. doi: 10.1186/s12885-018-4171-6.

引用本文的文献

1
Rare Breast Cancers Review.罕见乳腺癌综述
Healthcare (Basel). 2024 Dec 9;12(23):2483. doi: 10.3390/healthcare12232483.
2
The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status.乳腺浸润性大汗腺癌中肿瘤浸润淋巴细胞与HER2状态的相关性评估。
Biomol Biomed. 2024 Mar 11;24(2):256-261. doi: 10.17305/bb.2023.9868.

本文引用的文献

1
An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.乳腺大汗腺癌的分子和临床特征的最新研究进展。
Clin Breast Cancer. 2022 Jun;22(4):e576-e585. doi: 10.1016/j.clbc.2021.12.009. Epub 2021 Dec 27.
2
Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.大汗腺癌：一种以三阴性乳腺癌为主的独特特征。
Ann Surg Oncol. 2021 Oct;28(10):5610-5616. doi: 10.1245/s10434-021-10518-9. Epub 2021 Aug 23.
3
Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type.
根据世界卫生组织分类，17 种特殊组织学亚型浸润性乳腺癌的特征和预后：与非特殊型浸润性癌的对比分析。
Breast Cancer Res Treat. 2020 Nov;184(2):527-542. doi: 10.1007/s10549-020-05861-6. Epub 2020 Aug 13.
4
Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.避免和缩短 I 期和 II 期三阴性乳腺癌的新辅助化疗：Ki-67 标记指数的重要性和对大汗腺型病变的认识。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820943246. doi: 10.1177/1533033820943246.
5
Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.三阴性大汗腺癌：一种罕见的病理亚型，比其他三阴性乳腺癌预后更好。
J Surg Oncol. 2020 Nov;122(6):1232-1239. doi: 10.1002/jso.26129. Epub 2020 Jul 15.
6
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.乳腺浸润性大汗腺癌：18 例纯三阴性大汗腺癌的临床病理特征和全面基因组分析。
Mod Pathol. 2020 Dec;33(12):2473-2482. doi: 10.1038/s41379-020-0589-x. Epub 2020 Jun 5.
7
Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.三阴性大汗腺癌的预后：一项基于人群的研究。
Cancer Med. 2019 Dec;8(18):7523-7531. doi: 10.1002/cam4.2634. Epub 2019 Oct 23.
8
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.EORTC 10994/BIG 1-00 三期研究中的分子大汗腺癌：新辅助化疗后的病理反应和临床结果。
Br J Cancer. 2019 Apr;120(9):913-921. doi: 10.1038/s41416-019-0420-y. Epub 2019 Mar 22.
9
Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.乳房大汗腺癌：两部分综述的第二部分。浸润性大汗腺癌、分子大汗腺特征以及免疫组化在乳腺大汗腺病变诊断中的应用。
J Clin Pathol. 2019 Jan;72(1):7-11. doi: 10.1136/jclinpath-2018-205485. Epub 2018 Nov 13.
10
A clinicopathologic study of invasive apocrine carcinoma of the breast: A single-center experience.乳腺浸润性大汗腺癌的临床病理研究：单中心经验
Breast J. 2018 Nov;24(6):1105-1108. doi: 10.1111/tbj.13140. Epub 2018 Sep 21.